1. Home
  2. COSM vs BLRX Comparison

COSM vs BLRX Comparison

Compare COSM & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cosmos Health Inc.

COSM

Cosmos Health Inc.

HOLD

Current Price

$0.50

Market Cap

15.4M

Sector

Health Care

ML Signal

HOLD

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

HOLD

Current Price

$3.01

Market Cap

17.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COSM
BLRX
Founded
2009
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.4M
17.1M
IPO Year
2013
2011

Fundamental Metrics

Financial Performance
Metric
COSM
BLRX
Price
$0.50
$3.01
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$19.00
AVG Volume (30 Days)
616.4K
28.9K
Earning Date
11-17-2025
11-24-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$59,792,819.00
$12,735,000.00
Revenue This Year
$28.14
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.69
N/A
52 Week Low
$0.28
$2.30
52 Week High
$1.32
$14.70

Technical Indicators

Market Signals
Indicator
COSM
BLRX
Relative Strength Index (RSI) 38.52 37.42
Support Level $0.41 $3.14
Resistance Level $0.46 $3.36
Average True Range (ATR) 0.05 0.20
MACD 0.00 -0.01
Stochastic Oscillator 37.87 0.00

Price Performance

Historical Comparison
COSM
BLRX

About COSM Cosmos Health Inc.

Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: